loading
Precedente Chiudi:
$375.63
Aprire:
$377.03
Volume 24 ore:
3.68M
Relative Volume:
2.07
Capitalizzazione di mercato:
$94.13B
Reddito:
$11.42B
Utile/perdita netta:
$3.64B
Rapporto P/E:
26.20
EPS:
13.99
Flusso di cassa netto:
$3.50B
1 W Prestazione:
-20.68%
1M Prestazione:
-21.40%
6M Prestazione:
-21.90%
1 anno Prestazione:
-21.34%
Intervallo 1D:
Value
$364.66
$381.00
Intervallo di 1 settimana:
Value
$364.66
$473.37
Portata 52W:
Value
$364.66
$519.88

Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile

Name
Nome
Vertex Pharmaceuticals Inc
Name
Telefono
(617) 341-6393
Name
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Name
Dipendente
6,100
Name
Cinguettio
@VertexPharma
Name
Prossima data di guadagno
2025-02-10
Name
Ultimi documenti SEC
Name
VRTX's Discussions on Twitter

Confronta VRTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
366.54 98.88B 11.42B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.00 58.84B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
438.93 56.12B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
661.83 41.20B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
288.18 35.49B 3.81B -644.79M -669.77M -6.24

Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-08-06 Aggiornamento Wells Fargo Equal Weight → Overweight
2025-05-07 Downgrade Wolfe Research Outperform → Peer Perform
2025-05-06 Downgrade Leerink Partners Outperform → Market Perform
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-02-12 Aggiornamento Canaccord Genuity Sell → Hold
2025-02-11 Aggiornamento Canaccord Genuity Sell → Hold
2025-01-30 Downgrade Wells Fargo Overweight → Equal Weight
2024-12-20 Reiterato H.C. Wainwright Buy
2024-12-19 Downgrade Oppenheimer Outperform → Perform
2024-12-09 Aggiornamento Jefferies Hold → Buy
2024-11-14 Iniziato Citigroup Buy
2024-10-16 Iniziato Scotiabank Sector Perform
2024-10-10 Ripresa Raymond James Mkt Perform
2024-08-05 Downgrade Barclays Overweight → Equal Weight
2024-06-27 Iniziato Redburn Atlantic Buy
2024-04-11 Aggiornamento Evercore ISI In-line → Outperform
2024-02-15 Iniziato Wolfe Research Outperform
2024-02-06 Downgrade Evercore ISI Outperform → In-line
2024-02-02 Downgrade Bernstein Outperform → Mkt Perform
2024-01-31 Downgrade Maxim Group Buy → Hold
2024-01-31 Downgrade Robert W. Baird Neutral → Underperform
2024-01-24 Downgrade Canaccord Genuity Hold → Sell
2023-12-14 Reiterato RBC Capital Mkts Sector Perform
2023-05-30 Iniziato William Blair Outperform
2023-05-04 Ripresa Piper Sandler Overweight
2023-03-21 Iniziato Bernstein Outperform
2023-01-18 Iniziato Canaccord Genuity Hold
2023-01-17 Aggiornamento SVB Leerink Mkt Perform → Outperform
2022-12-19 Downgrade Jefferies Buy → Hold
2022-07-13 Iniziato Cantor Fitzgerald Overweight
2022-06-01 Aggiornamento Maxim Group Hold → Buy
2022-05-23 Iniziato SVB Leerink Mkt Perform
2022-05-06 Downgrade Robert W. Baird Outperform → Neutral
2022-05-03 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2022-02-03 Downgrade RBC Capital Mkts Outperform → Sector Perform
2022-01-27 Reiterato JP Morgan Overweight
2022-01-27 Reiterato Morgan Stanley Underweight
2022-01-27 Reiterato RBC Capital Mkts Outperform
2022-01-27 Reiterato Stifel Hold
2022-01-27 Reiterato Wolfe Research Outperform
2022-01-20 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-12-09 Iniziato Wells Fargo Overweight
2021-11-19 Iniziato BMO Capital Markets Market Perform
2021-11-19 Downgrade Piper Sandler Overweight → Neutral
2021-09-09 Downgrade Stifel Buy → Hold
2021-09-07 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-07-20 Downgrade SVB Leerink Mkt Perform → Underperform
2021-07-19 Ripresa Wolfe Research Outperform
2021-07-01 Iniziato Raymond James Mkt Perform
2021-06-11 Downgrade Daiwa Securities Outperform → Neutral
2021-02-23 Aggiornamento Robert W. Baird Neutral → Outperform
2021-02-02 Reiterato H.C. Wainwright Buy
2020-12-30 Iniziato Daiwa Securities Outperform
2020-11-30 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2020-11-20 Iniziato Bernstein Outperform
2020-10-28 Iniziato UBS Buy
2020-07-31 Reiterato H.C. Wainwright Buy
2020-07-08 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-04-30 Reiterato H.C. Wainwright Buy
2020-04-28 Downgrade RBC Capital Mkts Outperform → Sector Perform
2020-03-04 Iniziato Barclays Overweight
2020-01-31 Downgrade Robert W. Baird Outperform → Neutral
2019-11-19 Aggiornamento Guggenheim Neutral → Buy
2019-11-12 Iniziato SunTrust Buy
2019-10-17 Ripresa BofA/Merrill Buy
2019-09-03 Aggiornamento Goldman Neutral → Buy
2019-08-01 Downgrade Needham Buy → Hold
2019-05-23 Ripresa Citigroup Buy
2019-05-21 Iniziato Credit Suisse Outperform
2019-04-12 Iniziato Evercore ISI In-line
2019-03-26 Aggiornamento William Blair Mkt Perform → Outperform
2019-03-19 Downgrade SVB Leerink Outperform → Mkt Perform
2019-02-06 Downgrade Maxim Group Buy → Hold
Mostra tutto

Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie

pulisher
01:23 AM

Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat - MSN

01:23 AM
pulisher
12:53 PM

South African Patient Groups Urge Antitrust Probe into Vertex Pharmaceuticals Over Cystic Fibrosis Drug Pricing - geneonline.com

12:53 PM
pulisher
Aug 08, 2025

Advocates urge South Africa to reopen antitrust probe into Vertex Pharmaceuticals - statnews.com

Aug 08, 2025
pulisher
Aug 08, 2025

The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals' Headquarters in Boston Seaport District - MarketScreener

Aug 08, 2025
pulisher
Aug 07, 2025

Stock Analysis | Vertex Pharmaceuticals OutlookNavigating Mixed Signals and Market Uncertainty - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Vertex Pharma CEO Kewalramani buys shares worth $3.89 million - Investing.com

Aug 07, 2025
pulisher
Aug 07, 2025

RMR Group secures $1 billion mortgage for Vertex Pharmaceuticals HQ By Investing.com - Investing.com Australia

Aug 07, 2025
pulisher
Aug 07, 2025

The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals’ Headquarters in Boston Seaport District - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat - MSN

Aug 07, 2025
pulisher
Aug 07, 2025

Vertex Pharmaceuticals (VRTX) Hits New All-Time Low on Failed Clinical Trial - MSN

Aug 07, 2025
pulisher
Aug 07, 2025

Vertex Pharmaceuticals Reports Q2 2025 Revenue Growth, Net Income Turns Positive Amidst Challenges - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Vertex Pharmaceuticals (VRTX) Reports Strong Q2 2025 Revenue Growth with US$2,965 Million - Yahoo Finance

Aug 07, 2025
pulisher
Aug 06, 2025

Entrada (TRDA) Q2 Revenue Drops 98% - The Motley Fool

Aug 06, 2025
pulisher
Aug 06, 2025

Vertex Pharmaceuticals: Guggenheim maintains a 'Buy' Rating, The Target Price is $546 - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

The Escalator: Geron, Vertex Pharmaceuticals, Butler/Till and more - Medical Marketing and Media

Aug 06, 2025
pulisher
Aug 06, 2025

Vertex Pharmaceuticals Shares Rise After Upgrade From Wells Fargo - MarketScreener

Aug 06, 2025
pulisher
Aug 06, 2025

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 06, 2025
pulisher
Aug 06, 2025

Vertex stock price target lowered to $411 by Canaccord on mixed pipeline updates - Investing.com

Aug 06, 2025
pulisher
Aug 06, 2025

Vertex Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Aug 06, 2025
pulisher
Aug 06, 2025

Vertex tops estimates on cystic fibrosis treatment strength, new products - MSN

Aug 06, 2025
pulisher
Aug 06, 2025

Vertex’s Journavx successor culled after falling short in Phase II trial - Yahoo Finance

Aug 06, 2025
pulisher
Aug 06, 2025

7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip - MSN

Aug 06, 2025
pulisher
Aug 06, 2025

Vertex Pharmaceuticals Reports Strong Q2 2025 Growth - The Globe and Mail

Aug 06, 2025
pulisher
Aug 05, 2025

Vertex Pharmaceuticals: Strong Growth and Strategic Advances - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex falls after FDA doubts broad use of chronic pain drug - The Boston Globe

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex Pharmaceuticals Reports 12% Revenue Increase in Q2 2025 - The Globe and Mail

Aug 05, 2025
pulisher
Aug 05, 2025

Growing, pain: Journavx on the move as Vertex reports 2Q hitches - BioWorld MedTech

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex Pharmaceuticals Halts Development of VX-993 After Phase II Trial Fails to Show Pain Relief Benefit - geneonline.com

Aug 05, 2025
pulisher
Aug 05, 2025

Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex Pharmaceuticals stock hits 52-week low at $377.78 - Investing.com

Aug 05, 2025
pulisher
Aug 05, 2025

Weakness In Vertex Stock Seen As Buying Opportunity - Benzinga

Aug 05, 2025
pulisher
Aug 05, 2025

These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results - Benzinga

Aug 05, 2025
pulisher
Aug 05, 2025

Cantor Equity Partners, Inc. shares fall 2.41% intraday as Vertex Pharmaceuticals' price targets are adjusted by multiple analysts. - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex stock price target lowered to $478 at H.C. Wainwright on pain program setbacks - Investing.com Australia

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex Pharmaceuticals: A Long-Term Growth Story Fueled by Financial Discipline and Pipeline Breakthroughs - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex’s strong quarter unable to undo pain from VX-993 woes - The Pharma Letter

Aug 05, 2025
pulisher
Aug 05, 2025

VRTX: Vertex Shares Tank After Pain Drug Flop in Key Trial - TradingView

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex VX-993 Misses Primary Endpoint in Mid-Stage Trial, Ending Investigation for Acute Pain - Patient Care Online

Aug 05, 2025
pulisher
Aug 05, 2025

Relative Strength Alert For Vertex Pharmaceuticals - Nasdaq

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex Non-Opioid Pain Drug Flunks Proof-of-Concept Test, Ending Plans for a Pivotal Study - MedCity News

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex Pharmaceuticals Stock Falls 15% After Failed Drug TrialNews and Statistics - IndexBox

Aug 05, 2025
pulisher
Aug 05, 2025

VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex Pharmaceuticals' Q2 2025 Earnings and JOURNAVX Strategy Discrepancies: Assessing Long-Term Viability Amid Short-Term Volatility - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex Pharmaceuticals: Navigating Short-Term Setbacks to Unlock Long-Term Value in a High-Stakes Biotech Landscape - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex narrows near-term development plan for Journavx after FDA naysays broad label in neuropathic pain - Fierce Pharma

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex Pharma plunges as trial setback overshadows Q2 beat - Seeking Alpha

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex Falls After FDA Doubts Broad Use of Chronic Pain Drug - Bloomberg.com

Aug 05, 2025
pulisher
Aug 05, 2025

Nasdaq 100 Movers: Axon Enterprise Leads Gains, Vertex Pharmaceuticals Declines - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex’s Pain Drug Failure Adds To Investor Doubts - insights.citeline.com

Aug 05, 2025
pulisher
Aug 05, 2025

Novo and Hims seem to give conflicting accounts on compounding demand - statnews.com

Aug 05, 2025
pulisher
Aug 05, 2025

Vertex Stock Tumbles After Strong Earnings. What’s Spooking Investors. - Barron's

Aug 05, 2025

Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$563.00
price up icon 0.57%
$438.93
price up icon 0.88%
$661.83
price down icon 1.56%
biotechnology ONC
$288.18
price down icon 3.39%
$111.66
price up icon 0.28%
Capitalizzazione:     |  Volume (24 ore):